Key Customer Lead
Alexion
Key Customer Lead
Alexion
Global biopharmaceuticals focusing on rare diseases
This is what you will do:
KCL(キーカスタマーリード)は、コマーシャルに所属しキーオピニオンリーダー(KOL)をリードし、会社の方向性を示すインサイト生成の戦略的実行をサポートする役割をになう部門である。
KCLはアレクシオンのCSP(コマーシャル・スピーカー・プログラム)の計画と実行において、マーケティング、セールス、およびその他の関連チームと連携して活動する。その為、KCLのメンバーには、チームワーク、コラボレーション、および高度な専門的知識が必要とされ、加えてアレクシオンのカルチャーの中で成長するチームプレーヤーが望まれる。
KCLは、コマーシャル組織におけるフィールドベースのシニアポジションでBU headの直属となる。
You will be responsible for:
You will need to have:
We would prefer for you to have:
Date Posted
01-9月-2026Closing Date
29-11月-2026Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact [email protected]. Alexion participates in E-Verify.
Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion